The Pharma Data

JANUARY 20, 2021

After each data review, the DSMC will advise the study Steering Committee with recommendations for protocol modifications, if concerns over safety have developed, or that the study should continue according to the protocol if no concerns are identified. His publication list includes more than 475 articles and 7 book chapters.

Trials 52

Trials Cardiology Containment Development 52

Delveinsight

JULY 22, 2021

Joachim Fruebis, chief development officer of BlueRock, said that receiving fast track designation from the FDA is a crucial step, which will help them further progress clinical development of their DA01 cell therapy approach for Parkinson’s disease. Both use machine learning to draw this information from MRI scans.

Cardiology 98

Cardiology Development Engineer Clinical Trials 98

The Pharma Data

JULY 12, 2021

Up to 40% of all patients with type 2 diabetes develop chronic kidney disease. The clinical data from FIGARO-DKD are scheduled for presentation at the European Society of Cardiology (ESC) Congress 2021 on August 28th. Up to 40% of all patients with type 2 diabetes develop CKD. The study met its primary endpoint.

FDA Approval 52

FDA Approval Cardiology Medicine Trials 52

The Pharma Data

AUGUST 30, 2021

Professor of Cardiology at the National and Kapodistrian University of Athens, Greece, and co-principal investigator of the FIDELIO-DKD and FIGARO-DKD Phase III clinical trials. Up to 40% of all patients with type 2 diabetes develop chronic kidney disease.

HR 52

HR Cardiology Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 28, 2021

The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. Bayer is committed to drive sustainable development and generate a positive impact with its businesses.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Branding 52

The Pharma Data

SEPTEMBER 11, 2021

Results from EMPEROR-Preserved were presented at the European Society of Cardiology Congress 2021 on August 27 and published in The New England Journal of Medicine. vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc.

Medicine 52

Medicine Insulin FDA Approval Trials 52

The Pharma Data

NOVEMBER 11, 2021

Bayer and its development mate MSD moment blazoned the launch of VICTOR (VerICiguaT in grown-ups with Habitual heart failure and Reduced ejection bit), a new Phase III cardiovascular study probing the expanded use of heart failure (HF) treatment vericiguat. The vericiguat program is beingco-developed by Bayer and MSD.

Cardiology 40

Cardiology Branding Development Production 40

XTalks

NOVEMBER 19, 2021

While cardiac biomarkers hold much promise, there are a number of challenges in developing robust markers that can accurately reflect changes in disease biology linked to the mechanism of action of a therapeutic intervention. This is a part of the precision cardiology approach and could lead to their use as prognostic indicators.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

XTalks

JANUARY 19, 2024

Regulatory bodies have demonstrated preparedness for the surge in radiopharmaceuticals as evidenced by inaugural Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) programs to expedite commercial manufacturing, US Food and Drug Administration (FDA) approvals and marketing authorizations.

DNA 66

DNA Radiology FDA Approval Development 66

XTalks

AUGUST 2, 2023

We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. is a global pharmaceutical company, working across both developed and emerging markets. Pfizer Inc. billion, a 26.55 percent decline from the $3.19

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JULY 8, 2021

. “No approved therapies have been clinically proven to improve outcomes specifically for people with HFpEF, leaving a significant unmet medical need in this already prevalent and increasingly common form of heart failure,” said Mohamed Eid, M.D., vice president, Product Development, Lilly.

Trials 52

Trials Doctors Doctor Medicine 52

pharmaphorum

OCTOBER 8, 2020

RHYTHM AI will expand the research, using a multi-centre clinical trial designed to be a ‘real-world’ evaluation of the STAR Mapping System as a potential treatment for patients undergoing cardiac ablation procedure for persistent AF. The post RHYTHM AI cleared for large trial of atrial fibrillation mapping tool appeared first on.

Trials 52

Trials Clinical Trials Clinical Trials Clinical Development 52

The Pharma Data

SEPTEMBER 15, 2020

(NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on multiple fronts, including new data on the BNT162b2 vaccine candidate being developed in collaboration with BioNTech SE. UPDATES ON COVID-19 DEVELOPMENT PROGRAMS.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52